377 related articles for article (PubMed ID: 32315980)
1. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Novi G; Mikulska M; Briano F; Toscanini F; Tazza F; Uccelli A; Inglese M
Mult Scler Relat Disord; 2020 Jul; 42():102120. PubMed ID: 32315980
[TBL] [Abstract][Full Text] [Related]
2. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
4. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Gemcioglu E; Davutoglu M; Ozdemir EE; Erden A
Mult Scler Relat Disord; 2020 Jul; 42():102196. PubMed ID: 32480326
[TBL] [Abstract][Full Text] [Related]
5. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Wurm H; Attfield K; Iversen AK; Gold R; Fugger L; Haghikia A
Mult Scler; 2020 Sep; 26(10):1261-1264. PubMed ID: 32762494
[TBL] [Abstract][Full Text] [Related]
6. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
7. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
8. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
9. Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?
Vakil-Gilani K; O'Rourke K
Clin Rheumatol; 2020 Jul; 39(7):2067-2068. PubMed ID: 32474884
[No Abstract] [Full Text] [Related]
10. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
11. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
Balasubramanian S; Nagendran TM; Ramachandran B; Ramanan AV
Indian Pediatr; 2020 Jul; 57(7):681-683. PubMed ID: 32393681
[No Abstract] [Full Text] [Related]
12. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
[No Abstract] [Full Text] [Related]
15. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Rejdak K; Grieb P
Mult Scler Relat Disord; 2020 Jul; 42():102163. PubMed ID: 32388458
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
18. May IL-17 have a role in COVID-19 infection?
Megna M; Napolitano M; Fabbrocini G
Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
[No Abstract] [Full Text] [Related]
19. COVID-19 in multiple sclerosis: The Dutch experience.
Loonstra FC; Hoitsma E; van Kempen ZL; Killestein J; Mostert JP
Mult Scler; 2020 Sep; 26(10):1256-1260. PubMed ID: 32662742
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 in patients with myasthenia gravis.
Anand P; Slama MCC; Kaku M; Ong C; Cervantes-Arslanian AM; Zhou L; David WS; Guidon AC
Muscle Nerve; 2020 Aug; 62(2):254-258. PubMed ID: 32392389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
